Unicycive Therapeutics, Inc.
News
Unicycive Therapeutics (NASDAQ:UNCY) Earns Speculative Buy Rating from Benchmark
Ticker Report Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report)s stock had its "speculative buy" rating reaffirmed by research analysts at Benchmark in a research note issued on Friday, Marketbeat...\n more…
Buy Rating Maintained for Unicycive Therapeutics Amidst OLC NDA Submission and Strong Financial Outlook
TipRanks Financial Blog Maxim Group analyst Jason McCarthy has maintained their bullish stance on UNCY stock, giving a Buy rating on September 3. Jason McCarthy has given ...\n more…
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire LOS ALTOS, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...\n more…
Unicycive Therapeutics (NASDAQ:UNCY) Stock Rating Reaffirmed by HC Wainwright
Ticker Report Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report)s stock had its "buy" rating reissued by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a...\n more…
Shilpa Medicare update on its CDMO customer - Unicycive Therapeutics
Business Standard - Markets & Investing Unicycive submits NDA to USFDA for Oxylanthanum Carbonate...\n more…
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic
Globe Newswire LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...\n more…